A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

Clinical trial NCT07010419 · RECRUITING

Trial details

NCT number: NCT07010419
Sponsor: Allist Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

NSCLC Adjuvant Treatment

Start date: 2025-05-28
Primary completion: 2028-10-31
Enrollment: 338

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.